Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. - Wikidata - awgldk - TriplyDB

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

http://www.wikidata.org/entity/Q44919656

about

Clinical management of localized colon cancer with capecitabine Molecular origins of cancer: Molecular basis of colorectal cancer GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer Molecular testing to optimize therapeutic decision making in advanced colorectal cancer Single Nucleotide Polymorphisms as Prognostic and Predictive Factors of Adjuvant Chemotherapy in Colorectal Cancer of Stages I and II Implications of mismatch repair-deficient status on management of early stage colorectal cancer Targeting colorectal cancer stem cells using curcumin and curcumin analogues: insights into the mechanism of the therapeutic efficacy Management of colorectal cancer Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?Chemotherapy-induced peripheral neurotoxicity: a critical analysis Lifestyle Factors in Cancer Survivorship: Where We Are and Where We Are Headed Management of locally advanced and metastatic colon cancer in elderly patients Antineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicity The X-ray structure of the complex formed in the reaction between oxaliplatin and lysozyme MicroRNA-218 is a prognostic indicator in colorectal cancer and enhances 5-fluorouracil-induced apoptosis by targeting BIRC5.CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer Role of surgery for colorectal cancer in the elderly Radix Astragali-Based Chinese Herbal Medicine for Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 mont Systematic review and meta-analysis of preoperative chemoradiotherapy with or without oxaliplatin in locally advanced rectal cancer.2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised co SR 57746A/xaliproden, a non-peptide neurotrophic compound: prospects and constraints for the treatment of nervous system diseases.Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation.Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer Assessing the quality of initial consultations regarding adjuvant colon cancer therapy

P2860

Q24611758-598ECF3D-700F-45A0-B4CD-DED1493A1FCF Q24617331-A6745FB3-549D-43CF-B5BD-22054C887257 Q24641833-C2FFFEB9-56A4-4413-B3D2-A7233045E612 Q24647888-A86C1064-D85A-41EE-80B9-D0EFC6C5DAA2 Q24653016-D4237422-29B6-43DC-A09B-0AF02D143283 Q24815800-72079AD9-C396-417B-9B7F-A10104A50A3D Q26749012-1FC8C270-95DD-4C70-92E7-4793AD802296 Q26765344-CBE3329C-679C-44A1-BBEB-C18D948296E9 Q26772272-B6E7C36F-D241-4BC3-9F2A-05BC1FD915CE Q26784365-A8C70766-0891-46EB-866F-1F8A2FA6F443 Q26823550-725BBDBE-E6AE-42AD-BB95-A3FE615D9373 Q26830362-991E8B3A-1017-41C4-B87E-1000091B8A87 Q27010318-A966524F-FB11-4E13-85A6-954176072447 Q27011454-9FF4B6F3-B3E7-4C1D-8E31-0EF563B97FCA Q27026129-7C7C90C6-A236-4523-A300-AF8F8801BA20 Q27305830-E3B069CD-B86A-4CA7-B3AE-AA9B1CE19F04 Q27690763-C176284C-78A6-49E7-A11C-728BC7448885 Q27853222-62E0765D-6A05-4555-9D57-A510A9B57A31 Q27853326-009629A4-7F70-4F9E-BE82-7407B1190BD6 Q28072444-BD25FD1A-BD2E-48BC-93F7-44FF7100F9B1 Q28078875-F567E151-869D-4FD1-BCE9-507E3724A031 Q28080176-F5E8441F-E5A3-4FA1-A1B0-27A6C9C2ADD4 Q28270819-33E1F66C-4ED3-40FA-9E48-2A5AE43F376B Q28484947-DAFFBFBA-5B67-414D-A49E-B153F3107BB2 Q28534572-29F96E1C-5F4D-4275-BBC3-20F6983D3259 Q28546068-BDED048D-D2CB-40BF-9599-0434E6A2C9CA Q28552023-7A3F8D39-DD58-430F-A573-DD675FDD45A4 Q28681140-F5B782B5-7D34-4422-A91D-EA5B37C84664 Q30235044-3F812D70-A317-4418-80C3-B7569121AB38 Q30239808-B5AA8EBB-66C7-4D61-8766-E57FAC1D1BB9 Q30301332-33E11500-304B-4230-8A7E-863F7A7BCB0E Q30315675-A38495B6-0BB6-45E4-B408-C4C38DB24339 Q30316930-1C7B4E47-8FE7-43EB-844F-DBD47940AA16 Q30318977-BD648DB9-6352-47BA-93CD-9C69A100615E Q30417975-D9D9F02D-6C3B-482E-BBE0-8E07FFC09D73 Q30418160-C04A16D9-9DB1-47C2-A372-AF87FD1437E0 Q30418988-E3576935-4715-4EF3-89AE-F434E269B144 Q30422095-0D6429BB-2596-405A-8BFB-FCECCB174F7B Q30422446-CDD7A171-AE04-4BE1-8D37-2E3A51186D81 Q30435841-9F6A8397-8FE5-41D2-B6E5-2A49AD86E54A

P2860

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

http://www.wikidata.org/entity/Q44919656

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

@en

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

@nl

type

label

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

@en

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

@nl

prefLabel

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

@en

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

@nl

P1433

Q44919656-09364E89-F02E-4AF4-8D5E-AC945FFB773F

P1476

Q44919656-CFEE4068-278A-40CB-9AFC-2DD333A446B5

P2093

Q44919656-05EAA3E1-72E3-4F43-B8CC-DD950DE46CE3

Q44919656-2A2641E1-D2FB-48FB-9D56-5B40B8595F0E

Q44919656-493CA5F1-5BF0-4CF9-BDAE-9B70707B20C2

Q44919656-5EC0FD1C-17B6-439C-A40B-1A301D5E303C

Q44919656-6C5883E7-6317-4396-A8D8-C8A5D9294521

Q44919656-76C871DF-C731-4A29-9574-A35C5388E0C4

Q44919656-A0127208-F8A2-43A6-8815-CE3465E57755

Q44919656-AE87FB2C-2DBB-458B-88F7-2966B8A602C8

Q44919656-B9BCF9B6-AC1C-4AEE-9F40-7AC440C24F8B

Q44919656-BE70B6EC-B097-4D49-9EDC-08AA5BDE7D27

P304

Q44919656-FDA762B3-679B-43CC-A94C-4BACC1D188A7

P31

Q44919656-3BB222AA-7F7F-4F8B-8205-14F033F16DAC

P356

Q44919656-F2B6F12B-3EF3-4E91-B86C-9552C4C1F426

P407

Q44919656-D1C476BE-2872-4984-BB7B-02AAE2F12E69

P433

Q44919656-3AA7704D-D24C-4D59-8A37-2D4AD21B93F4

P478

Q44919656-DC9E57A9-1953-412B-916D-9847068B416A

P50

Q44919656-076EB039-4066-49D1-8F5C-0007E92B44A2

Q44919656-8A5A1F34-AD65-4555-BD14-A3AC7D7C4764

P577

Q44919656-3E4CD686-5C0F-492D-A73B-DFF08033B9C4

P698

Q44919656-70789007-60A7-479B-A38B-49D7579254C9

P356

P1433

The New England Journal of Medicine

P1476

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer

@en

P2093

Aimery de Gramont

http://www.w3.org/2001/XMLSchema#string

Clare Topham

http://www.w3.org/2001/XMLSchema#string

Corrado Boni

http://www.w3.org/2001/XMLSchema#string

Isabelle Tabah-Fisch

http://www.w3.org/2001/XMLSchema#string

John Bridgewater

http://www.w3.org/2001/XMLSchema#string

Lamia Mounedji-Boudiaf

http://www.w3.org/2001/XMLSchema#string

Marta Zaninelli

http://www.w3.org/2001/XMLSchema#string

Matilde Navarro

http://www.w3.org/2001/XMLSchema#string

Multicenter International Stud ...... Cancer (MOSAIC) Investigators

http://www.w3.org/2001/XMLSchema#string

Philip Clingan

http://www.w3.org/2001/XMLSchema#string

P304

2343-2351

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA032709

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

350

http://www.w3.org/2001/XMLSchema#string

P50

Josep Tabernero

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15175436

http://www.w3.org/2001/XMLSchema#string